<unk>  (INN) is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States on July 24, 2012 as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. However, it does not appear to affect the risk of death or the frequency steroids are needed. It is unclear if it differs from the similar medication tiotropium or other commonly used medications from the class of LAMAs.<unk>  is delivered via a multidose dry powder inhaler, the Genuair inhaler. It is on the World Health Organization's List of Essential Medicines.
Aclidinium bromide
Umeclidinium bromide
Chloropicrin
Tiratricol
Bifluranol
Hydrastine
Brinzolamide
Pirisudanol